Phase I Clinical Trial

Corporate Partner

Drug

QBI-139 (human pancreatic-type ribonuclease endowed with toxicity for cancer cells)

Goals

• To evaluate the toxicity and tolerability of QBI-139 in patients with advanced, refractory solid tumors
• To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors

Sites

1. MD Anderson Cancer Center
2. University of Wisconsin Carbone Cancer Center (Protocol No. CO08912)